Navigation Links
Genetically corrected blood cells obtained from skin cells from Fanconi anemia patients
Date:6/2/2009

A collaboration research carried out by the teams of Jordi Surralls, Universitat Autnoma de Barcelona (UAB); Juan Carlos Izpisa-Belmonte and ngel Raya, Centre for Regenerative Medicine of Barcelona (CMRB); and Juan Antonio Bueren, Centre for Energetic, Environmental and Technological Research (CIEMAT), has resulted in the generation of blood cells from skin cells of patients with a genetic disease known as Fanconi anemia. The process is based on gene therapy and cell reprogramming techniques in which cells similar to embryonic stem cells known as induced pluripotent stem (iPS) cells can be generated. The research article was published in this week's digital version of Nature.

The research demonstrates that, for the first time, in the case of a genetic disease such as Fanconi anemia it is possible to correct the genetic defect in patient-specific skin cells by converting them into cells similar to embryonic stem cells (iPS cells) which later can be differentiated towards blood cells.

These results are the proof of concept that this new therapeutic strategy has the potential of generating tissues using the very skin of those affected with these genetic diseases. This observation is particularly important in diseases such as Fanconi anemia, where one of the main problems lies in the lack of blood cell in the bone marrow of those affected. However, according to researchers, this new therapeutic strategy can be applied to many other genetic diseases by differentiating iPS cells towards healthy tissues these patients lack.

The generation of blood cells in this research was carried out in vitro, in cell culture plates, which places the research in a preclinical environment. It remains unknown whether they would generate blood cells after being transplanted. Moreover, the transplant of embryonic stem cells in animals has revealed that these cells can cause tumours. Therefore, the possibility of treating Fanconi anemia patients by tr
'/>"/>

Contact: Maria Jesus Delgado
MariaJesus.Delgado@uab.cat
34-935-814-049
Universitat Autonoma de Barcelona
Source:Eurekalert

Page: 1 2

Related biology news :

1. Penn Veterinary Medicine report new strategy to create genetically-modified animals
2. Study shows genetically engineered corn could affect aquatic ecosystems
3. Genetically engineered corn may harm stream ecosystems
4. Genetically modified carrots provide more calcium
5. Is political orientation transmitted genetically?
6. Total, genetically-based recall
7. Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants
8. Researchers genetically link Lou Gehrigs disease in humans to dog disease
9. Scientists unlock possible aging secret in genetically altered fruit fly
10. Cats eye diseases genetically linked to diseases in humans
11. Origins of wolverine in California genetically verified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... YORK and POINT ROBERTS, Washington ... news source covering leading sectors including technology and tech stocks, ... Privacy marketplace featuring master pickpocket and security consultant Apollo ... is stolen and talks about the Wocket™ biometric smart wallet, ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... are replaced through cell division. Researchers at Karolinska Institutet ... genetic information remains intact despite this continuous exchange of ... of the scientific journal Molecular Cell. , An adult ... which die and are replaced by cell division every ...
... the second major form of dementia. Under the ... Flanders Interuniversity Institute for Biotechnology (VIB) affiliated to ... the progranulin growth factor plays an important biological ... dementia. Because progranulin is known primarily for its ...
... scientists at Indiana University Bloomington report biochemical machinery ... weakest of scents. Even when ovary extracts were ... their mark. , A video demonstrating sperm chemotaxis ... can be downloaded at http://www.iuinfo.indiana.edu/bem/media_relations/movie.chemotaxis.mpg (Credit: Stephen ...
Cached Biology News:A protein complex that untangles DNA 2Researchers find cause of frontotemporal dementia 2Even when faint, ovary scent draws sperm cells 2
(Date:3/2/2015)... (PRWEB) March 02, 2015 Shimadzu Scientific ... and present on LCMS and marijuana analysis at the ... March 8 to 12 at the Ernest N. Morial ... can stop by booth 3121 to discuss laboratory challenges ... company’s innovative, proven products help save time, money and ...
(Date:3/2/2015)... YORK and VANCOUVER, British Columbia ... Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical ... cannabinoid based therapies, today announced that Craig ... company overview during a live webcast at VirtualInvestorConferences.com. ... ET LINK:   http://VirtualInvestorConferences.com > click the ...
(Date:3/2/2015)... SANTA BARBARA, Calif. , March 2, 2015 ... a biotechnology company developing therapies for autoimmune and ... Trademark Office (USPTO) has issued an important new ... immune system function through the targeting of CLIP. ... the targeted peptide technology underlying VG Life Sciences, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Increasing its efforts ... Films launches its first three episodes of The GMO TRUTH ... Project this month, as it continues its mission to discover ... the project's first phase, to “uncover the truth about the ... media. , The GMO Truth Podcast is an expansion of ...
Breaking Biology Technology:Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3InMed Pharmaceuticals to Present Investor Webcast March 5 2VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2
... Inc. (NYSE: MYL ),today announced that Mylan Pharmaceuticals ... Drug Administration (FDA) for its,Abbreviated New Drug Application (ANDA) ... 200 mg., Lamotrigine Tablets are the generic version ... $1.97 billion,for the 12 months ending Sept. 30, 2007., ...
... venture syndicate invests to advance expanding pipeline of products to ... ... Fovea Pharmaceuticals SA, a,biopharmaceutical company developing novel therapeutics for the ... in a,Series B financing from a strong, international syndicate of ...
... is,GlaxoSmithKline,s (NYSE: GSK ) response to ... Evaluative Sciences (ICES) titled,"Thiazolidinediones and Cardiovascular Outcomes ... that the ICES retrospective analysis of the ... and generates misleading,conclusions regarding acute myocardial infarction ...
Cached Biology Technology:Fovea Pharmaceuticals Completes EUR30M Series B Financing 2Fovea Pharmaceuticals Completes EUR30M Series B Financing 3Fovea Pharmaceuticals Completes EUR30M Series B Financing 4GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 2GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 3GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 4GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 5